key: cord-0735507-59wuf88m
authors: Belhassan, Assia; Chtita, Samir; Zaki, Hanane; Lakhlifi, Tahar; Bouachrine, Mohammed
title: Molecular docking analysis of N-substituted Oseltamivir derivatives with the SARS-CoV-2 main protease
date: 2020-05-31
journal: Bioinformation
DOI: 10.6026/97320630016404
sha: 5324fed1acca337b9ceaddaf7f0622231cf37a2f
doc_id: 735507
cord_uid: 59wuf88m

The identification of chemotherapeutic drugs against Novel Coronavirus (2019-nCoV) is a significant requirement due to the rapid rise in deaths due to Corona Viral Infection all around the world. Therefore, it is of interest to document the molecular docking analysis data of 32 N-substituted Oseltamivir derivatives inhibitors of influenza virus H5N1 with the Novel Coronavirus main protease (2019-nCoV). We describe the optimal binding features of Oseltamivir derivatives with the SARS-Cov-2 main protease (Code PDB: 6LU7) for further consideration.

©Biomedical Informatics (2020) Background: 2019 novel coronavirus (SARS-CoV-2) is reported in December 2019 in Wuhan (China). This infection has spread in the majority of countries and caused until early April 2020, 823 626 confirmed cases and 40 598 deaths according to the world health organization [1] [2] [3] . SARS-CoV-2 who causes COVID-19 is a member of Betacorona viruses like the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) and the Middle-East Respiratory Syndrome coronavirus (MERSHCoV) [4] . So far no drugs or vaccine against this virus has been reported, due to the long time of producing new medicines, repurposing medications may be the only way to fight this unexpected pandemic. Among the drugs proposed as antiviral agents of COVID-19, we selected Oseltamivir [2, 5] . To date, oseltamivir has been the first choice as an effective treatment for infections with influenza A and B, and has been widely used since its approval in 1999 [6] . Many papers reported the effect of chloroquine and hydroxy chloroquine in the treatment of COVID-19 [2,7-9], today these two drugs are used in different hospitals around the world as antiviral treatment of COVID-19 disease caused by SARS-CoV-2 virus [10, 11] . Based on this effect the study of interactions of chloroquine, hydroxy chloroquine and thirty-two N-substituted Oseltamivir derivatives in the active site of SARS-CoV-2 main protease recently crystallized are recommended. Therefore, it is of interest to document the molecular docking analysis data of 32 N-substituted Oseltamivir derivatives inhibitors of influenza virus H5N1 with the Novel Coronavirus main protease (2019-nCoV) with known structure (Code PDB: 6LU7).

The studied compounds were evaluated against Novel Coronavirus (SARS-CoV-2 main protease) (Figure 1 and Table 1 ). The chemical compounds reported as potent avian influenza virus H5N1 inhibitors from N-substituted Oseltamivir derivatives were taken from literature [6] .

Each structure of 32 moleculesis sketched with Gauss View 05 program [12] , and optimized by DFT approach performed with Gaussian 09 program package [13] using the hybrid functional B3LYP [14] combining the Becke's three-parameter and the Lee-Yang-Parr exchange-correlation functional employing the 6-31G(d) basis set in gas phase [15] . The geometry of the compounds was determined by optimizing all geometrical variables with no symmetry constraint [16]. (2020) was set at 40×40×40 xyz points with grid spacing of 1 Å to cover the folic acid binding site in the enzyme and was generated by using the co-crystallized ligand (N3) as the center for docking. For Autodock Vina study, an extended PDB format, termed PDBQT, is used for cordonnante files, which includes atomic partial charges and atom types. Torsion angles were calculated to assign the flexible and nonbonded rotation of molecules.

Molecular docking was performed to find types of interactions and the binding affinity of studied molecules in the target. 32 different molecules have been evaluated for their affinity against the SARS-CoV-2 main protease (pdb code 6LU7). The results are presented in Table 2 . The best energies of interaction with the SARS-CoV-2 main protease (pdb code 6LU7) (lowest energy level) are observed for compounds N° 24, 28, 31 and 32 (Table 2) . So, these molecules could have more inhibitory potential of the studied enzyme than Chloroquine and Hydroxychloroquine. The structures of the molecules that have the best affinity in the binding site of SARS-CoV-2 main protease indicate that the present of the cycle and/or Fluorine atoms in the structure increase predicted inhibitory potential of these molecules against studied enzyme. The cocrystallized ligand taken from the crystal structure of studied enzyme is re-docked into the active site. It could be seen from (Figure 3) , shows π-π T-Shaped bond with His 41 residue, π-alkyl and alkyl interactions with Met165 residue. 

Gaussian 09 (Revision A. 1)

Dassault Systèmes BIOVIA Discovery Studio Modeling Environment

License statement: This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited